Corpus ID: 35995729

The impact of chemotherapy-induced nausea and vomiting.

@article{Morrow2014TheIO,
  title={The impact of chemotherapy-induced nausea and vomiting.},
  author={Gary R. Morrow},
  journal={Clinical advances in hematology \& oncology : H\&O},
  year={2014},
  volume={12 Suppl 9 3},
  pages={
          3-4
        }
}
  • G. Morrow
  • Published 1 March 2014
  • Medicine
  • Clinical advances in hematology & oncology : H&O
Chemotherapy-induced nausea and vomiting (CINV) has a broad range of consequences that can affect not only the patient’s general health status but also daily function and quality of life. Patients undergoing chemotherapy should be encouraged to maintain adequate nutritional and fluid intake to prevent the weight loss, electrolyte imbalances, and dehydration that can result from CINV. Patients also should be monitored closely for signs and symptoms of these problems because early intervention… Expand
Sustol (Granisetron) First Extended-Release 5-HT3 Receptor Antagonist Approved for the Prevention of Acute and Delayed CINV
TLDR
Chemotherapy-induced nausea and vomiting (CINV) can have a myriad of clinical consequences for patients, their families, and the healthcare system, including early treatment discontinuation; nonadherence to chemotherapy treatment; problems with appetite and eating; and higher direct and indirect costs of care. Expand
Varubi (Rolapitant) Approved for the Prevention of Delayed-Onset Chemotherapy-Induced Nausea and Vomiting
A critical part of care planning for patients with cancer is the prevention and management of chemotherapy-induced nausea and vomiting (CINV), one of the most feared side effects of chemotherapy.Expand
Cardiovascular Events in Cancer Patients Treated with Highly or Moderately Emetogenic Chemotherapy: Results from a Population-Based Study
Studies on cardiovascular safety in cancer patients treated with highly or moderately emetogenic chemotherapy (HEC or MEC), who may have taken the antiemetic, aprepitant, have been limited toExpand
A prospective pharmacovigilance study to evaluate adverse effect profile of first line anti-tubercular drugs in newly diagnosed sputum positive patients
TB is the most rampant communicable infectious disease on earth and remains out of control in many developing countries. It is the single most common cause of death in individuals aged 15-49 yrs. TBExpand
Physician Agency and Patient Survival.
TLDR
It is shown that an increase in health care supply due to a change in private physician incentives has a theoretically ambiguous impact on patient welfare, and a change to Medicare fees that caused physicians to increase their provision of chemotherapy improved patient survival. Expand

References

SHOWING 1-10 OF 14 REFERENCES
Chemotherapy-induced nausea and vomiting.
TLDR
The state of the science related to chemotherapy-induced nausea and vomiting is examined and both pharmacologic and behavioral strategies that have demonstrated efficacy in managing these distressing symptoms are reviewed. Expand
Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology.
  • R. Gralla, D. Osoba, +12 authors D. Pfister
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
TLDR
Goals related to the complete control of emesis, ie, no vomiting, include providing care that is convenient for the patient, treatment that reduces hospitalization and time in the ambulatory setting, and therapy that enhances the patient’s quality of life. Expand
Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.
TLDR
Patients about to receive moderately or highly emetogenic chemotherapy should be screened for these factors and additional measures, such as behavior modification and modification of antiemetic therapy, should be considered in attempts to improve the control of PCNV. Expand
Effect of postchemotherapy nausea and vomiting on health-related quality of life
TLDR
PCNV adversely affects several quality-of-life domains, but patients with only nausea experience less disruption than do those with both nausea and vomiting, and by 2–4 weeks after chemotherapy all HQL scores had either returned to their baseline levels or were better than baseline. Expand
Differences in nausea, vomiting, and retching between younger and older outpatients receiving cancer chemotherapy.
TLDR
The pattern between the younger and older patients' N, V, and R subscale scores was consistent in that the younger patients' scores were consistently (except on one occasion) higher than the older Patients' scores, but this difference was statistically insignificant. Expand
The efficacy and cost effectiveness of new antiemetic guidelines.
TLDR
The new oral antiemetic regimen compared favorably with published data, was well-tolerated, and resulted in lower pharmacy and nursing costs, with a cost saving potential of $20,000 per year. Expand
5‐HT3 antiemetic therapy for patients with breast cancer
  • E. Perez
  • Medicine
  • Breast Cancer Research and Treatment
  • 2004
TLDR
The studies reviewed here indicate that the antiemetic efficacy of 5‐HT3 antagonists is equivalent in previously untreated patients receiving moderately emetogenic chemotherapy for breast cancer, depending on the doses and schedules utilized. Expand
NAUSEA AND VOMITING
Vomiting has long been regarded as one of the most unpleasant aspects of anaesthesia. In addition, it is a feature of many medical and surgical conditions and of travel by land, sea and air. ItsExpand
Incidence of chemotherapy‐induced nausea and emesis after modern antiemetics
The authors determined the incidence of acute and delayed chemotherapy‐induced nausea and emesis (vomiting) (CINV) among patients receiving highly (HEC) or moderately (MEC) emetogenic chemotherapy.Expand
Progress in preventing chemotherapy-induced nausea and vomiting.
  • M. Markman
  • Medicine
  • Cleveland Clinic journal of medicine
  • 2002
Our understanding of the pathophysiology of emesis has improved over the past 2 decades, and we now have drugs that can prevent acute emesis in most patients. Prevention and treatment of the delayedExpand
...
1
2
...